Leading-edge Oncolytic Virus Services Are Available to Advance Immunotherapy Research

January 14 18:06 2021
With the first oncolytic virus product obtaining US Food and Drug Administration approval, it has become a kind of powerful new therapeutic agents in cancer therapy. With years of exploration in this field, Creative Biolabs has updated oncolytic virus engineering and construction services.

New York, USA – January 14, 2021 – Recently, oncolytic viruses (OVs) have been taking the front stage in biological therapy for cancer. Ongoing extensive research has suggested that OVs, such as oncolytic adenovirus, herpes simplex virus and measles virus, can be potential candidates in cancer therapy. Considering their therapeutic efficacy and safety, as well as low side effects, the use of such engineered viruses in biological cancer therapy has the potential to establish a milestone in cancer research.

Equipped with leading-edge technologies and platforms in this field, the scientist team at Creative Biolabs has been focusing on OVs by updating related services and completing the product list. Now, it has optimized oncolytic virus engineering and construction services to cover the whole pipeline of oncolytic immunotherapy development.

• Oncolytic Virus Engineering

Creative Biolabs provides a one-stop solution of oncolytic virus engineering and the experienced scientists can manipulate the oncolytic virus to meet specific needs for clients’ research, preclinical study and drug development.

The featured services cover pathogenicity manipulation, and immunogenicity manipulation. Besides, Creative Biolabs has developed mature strategies to manipulate the OVs expressing customized antibody to increase efficacy and reduce toxicity, expressing cytokine/chemokine to enhance the anti-tumor immune response, and delivering the immune checkpoint inhibitors to the tumor environment.

• Oncolytic Virus Construction

With years of exploration in immunology and oncology, Creative Biolabs has established a comprehensive platform called OncoVirapy for oncolytic virus construction service.

By virtue of the OncoVirapy platform, Creative Biolabs is able to generate the most efficacious oncolytic viral vector covering Adenovirus, Herpes Simplex Virus, Measles Virus, Vaccinia Virus, Vesicular Stomatitis Virus, and Adeno-Associated Virus, enabling wider applications in oncolytic virotherapy of cancers.

“This OncoVirapy platform can not only facilitate oncolytic virus construction, but also help in other oncolytic virus development projects, such as in vitro assay for proof-of-concept study, in vivo assay for proof-of-concept study, and oncolytic virus manufacture,” as introduced by a senior scientist at Creative Biolabs, “and we will keep optimizing and expanding our services in cancer immunotherapy to meet the demand of next generation of cancer therapy.”

Detailed information about other oncolytic virus-related services and products at Creative Biolabs can be found on https://www.creative-biolabs.com/oncolytic-virus.

About Creative Biolabs

Empowered by leading technology and years of experience in biomedical science, Creative Biolabs has developed the OncoVirapy platform to support novel therapeutics development, providing comprehensive, end-to-end oncolytic virus therapy development services such as oncolytic virus engineering, construction, in vitro validation study, in vivo preclinical study, as well as first-class products (pre-made oncolytic viruses and oncolytic adenovirus construction kits).

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/oncolytic-virus